Clinical Trials Browser

Phase 2 × HIV Infections × Nivolumab × Clear all

NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections